GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Stella Pharma 4888.T · JPY

Health Care · Tokyo Stock Exchange · 🇯🇵 Japan

Compare

350

+1.45%

Close of 9 Nov 2026, in JPY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in JPY, from our data supplier.

FY2026

Revenue

¥323.4m

FY2019FY2026

Net income

−¥780.9m

FY2019FY2026

Free cash flow

−¥345.3m

FY2019FY2026

Shareholders' equity

¥2.43bn

FY2019FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue¥323.4m¥961.1m¥269.5m¥229.1m¥100.1m¥206.0m——
Gross profit¥250.6m¥828.7m¥203.7m¥192.4m¥50.7m¥165.2m−¥29.0m−¥24.2m
Research and development—¥328.4m¥393.6m¥374.3m¥255.2m¥307.5m¥441.4m¥436.0m
Operating income−¥749.0m−¥90.2m−¥760.3m−¥806.8m−¥761.0m−¥680.6m−¥951.4m−¥861.1m
Net income−¥780.9m−¥140.8m−¥763.7m−¥778.8m−¥767.7m−¥659.2m−¥962.2m−¥859.0m
Diluted earnings per share-22.34-4.14-22.44-24.94-26.77-23.01-27.53-24.58

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Total assets¥4.49bn¥5.42bn¥3.82bn¥4.33bn¥4.72bn¥2.05bn¥2.66bn¥3.62bn
Cash and short-term investments¥2.82bn¥3.21bn¥2.35bn¥2.71bn¥3.28bn¥1.25bn¥2.01bn¥2.99bn
Total liabilities¥2.06bn¥2.21bn¥1.44bn¥1.58bn¥1.64bn¥1.82bn¥1.97bn¥1.97bn
Debt¥747.1m¥766.8m¥933.3m¥1.09bn¥1.25bn¥1.41bn¥1.57bn¥1.60bn
Shareholders' equity¥2.43bn¥3.21bn¥2.38bn¥2.75bn¥3.08bn¥230.7m¥690.0m¥1.65bn
Shares outstanding35m34m34m31m29m29m35m35m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations−¥334.5m¥140.4m−¥876.8m−¥827.7m−¥1.08bn−¥772.8m−¥913.6m−¥771.3m
Capital spending−¥10.8m−¥3.9m−¥11.0m−¥25.4m−¥46.3m−¥20.8m−¥25.2m−¥10.5m
Free cash flow−¥345.3m¥136.5m−¥887.8m−¥853.1m−¥1.13bn−¥793.6m−¥938.8m−¥781.9m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue¥92.4m¥61.6m¥61.6m¥107.8m¥92.4m¥707.0m¥84.7m¥107.8m
Gross profit¥79.0m¥46.0m¥52.9m¥86.2m¥79.8m¥625.3m¥73.2m¥93.6m
Operating income−¥245.1m−¥243.5m−¥213.7m−¥147.1m−¥151.8m¥284.8m−¥105.9m−¥102.2m
Net income−¥228.8m−¥268.8m−¥204.2m−¥151.2m−¥156.7m¥232.8m−¥104.9m−¥107.0m
Diluted earnings per share-6.55-7.69-6.00-4.45-4.616.84-3.08-3.14
Total assets¥5.39bn¥4.49bn¥4.78bn¥4.92bn¥5.06bn¥5.42bn¥5.08bn¥5.21bn
Cash and short-term investments¥3.80bn¥2.82bn¥2.69bn¥2.80bn¥2.85bn¥3.21bn¥3.45bn¥3.75bn
Debt¥158.6m¥747.1m¥158.6m¥687.5m¥158.6m¥766.8m¥160.0m¥853.3m
Shareholders' equity¥3.22bn¥2.43bn¥2.70bn¥2.90bn¥3.05bn¥3.21bn¥2.97bn¥3.08bn

Growth per year

Compound annual rate

3 years5 years10 years
Revenue12.2%9.4%—
Operating income-2.4%1.9%—
Net income0.1%3.4%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin84.0%82.7%81.0%—
Operating margin-65.3%-135.0%-184.2%—
Net margin-71.8%-138.2%-186.3%—

Valuation history

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021
Price to earnings-17.7-49.0-23.9-11.4-14.9-40.0
Price to sales42.77.267.838.9114.6128.0

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.